MolecularMatch

MolecularMatch Through our website we help cancer patients and physicians find information about targeted therapies

With the increasing numbers of new mutations being tested and resulting drugs being developed, James Welsh M.D., founded MolecularMatch in 2014, a clinical informatics company whose primary goal is to improve the utility of genomics. Licensing clinical insights from MD Anderson, MolecularMatch developed a semi-automated technology that enhances the application of precision medicine for organizatio

ns. At our core, we are a technology company and believe that expert-created knowledge and real-time information are the pillars of an “informed decision support” solution. MolecularMatch’s patent pending automated technology reads and acquires thousands of genomic data sets weekly allowing our partners to efficiently provide evidence based Recommendations. The data set includes clinical trials, targeted drug treatments, mutations, genes, automated variant classifications, scientific abstracts/publications and more all of which contributes to our knowledge platform. Through Natural Language Processing we can examine and create associations among the information faster than any human can while applying the knowledge to our proprietary algorithms. Each of our solutions are founded in this technology allowing our decision support to be one of the most scientifically driven system known. Making the power of genetic data more discoverable, understandable, accessible and useful. MolecularMatch also offers patients and physicians a complimentary search tool that matches a patient’s genetic information from their disease to an appropriate therapy. The tool creates evidence-based treatment suggestions containing: 1) FDA-approved therapies, 2) experimental drugs that are currently being tested, and 3) appropriate clinical trials. Information provided by MolecularMatch is purely for informational purposes and should not take the place of information given by a physician or healthcare provider. The tool is available as a clinical lab integration product, or for free searching at www.MolecularMatch.com.

Take a look at these too videos in ➡️
05/19/2025

Take a look at these too videos in ➡️

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.

“Researchers also discovered that as leukemia cells drink up taurine, it promotes glycolysis (a breakdown of glucose to ...
05/18/2025

“Researchers also discovered that as leukemia cells drink up taurine, it promotes glycolysis (a breakdown of glucose to produce energy) to feed cancer growth.”

Read more about these latest discoveries about the effects of and ⬇️

Leukemia cells use taurine to produce energy and grow, a study in Nature by a Wilmot Cancer institute team shows.

“Incidence of 14 of the 33 cancer types increased in at least one of the younger age groups. Incidence of nine of these ...
05/09/2025

“Incidence of 14 of the 33 cancer types increased in at least one of the younger age groups. Incidence of nine of these 14 types also increased in at least one of the older age groups…” bit.ly/4387yGs

Read more from this study from the National Institutes of Health (NIH) ⬇️

Despite increasing incidence rates, cancer deaths in young people have not increased overall.

💻 Do you want to learn more about how we can help you? Take a look at our solutions to see how our technology can revolu...
05/06/2025

💻 Do you want to learn more about how we can help you? Take a look at our solutions to see how our technology can revolutionize your industry. With our solutions, we're sure you will find the best one!

www.molecularmatch.com

It’s Friday and what hat better way to end your week with a FREE trial of our technology! MMPower (API) for software eng...
05/02/2025

It’s Friday and what hat better way to end your week with a FREE trial of our technology! MMPower (API) for software engineers, or MMPortal for physicians, nurses and more.

Contact us at info@molecularmatch.com

Advanced clinical informatics knowledge base MMPower, a dynamic molecular search engine.

👨‍⚕️ Keep patients close to home with the power of MMPortal! With geo-located clinical trials, you will be sure your pat...
04/25/2025

👨‍⚕️ Keep patients close to home with the power of MMPortal! With geo-located clinical trials, you will be sure your patients get the best treatment and care.

Learn more about our technology at www.molecularmatch.com

A cancer epidemic in youth? What are researchers discovering to pinpoint this cancer at higher rates? ⬇️“Now, scientists...
04/25/2025

A cancer epidemic in youth? What are researchers discovering to pinpoint this cancer at higher rates? ⬇️

“Now, scientists report that exposure to colibactin in early childhood imprints a distinct genetic signature on the DNA of colon cells.”

Researchers have identified a potential culprit behind the alarming rise in early-onset colorectal cancer: a bacterial toxin called colibactin. Exposure to colibactin in early childhood imprints distinct patterns of DNA mutations that were significantly more common in early-onset cases.

🧬 Start your Monday with the power of MM technology! Learn how our software can get you the best results in precision me...
04/22/2025

🧬 Start your Monday with the power of MM technology! Learn how our software can get you the best results in precision medicine, clinical trials, and so much more!

Visit us today at www.molecularmatch.com

The significance of support and research throughout communities for those with cancer. Read more from CURE Today ⬇️“With...
04/21/2025

The significance of support and research throughout communities for those with cancer. Read more from CURE Today ⬇️

“With all the research advances, early studies can make a difference for patients across cancer subtypes.”

After nearly 30 years with cancer — community, research and education have helped us find hope, strength and purpose in the face of chronic blood cancers.

“The company’s lead drug candidate aims to help patients with acute myeloid leukemia (AML) who have experienced a relaps...
04/20/2025

“The company’s lead drug candidate aims to help patients with acute myeloid leukemia (AML) who have experienced a relapse or are unresponsive to other therapies.” 🧬 💊

Read more about this latest breakthrough from MaMassachusetts Institute of Technology (MIT)it.ly/4cCvBle

Founded by MIT researchers, Senti Bio is is working to create smarter cell therapies for cancer using synthetic biology. The company equips cells with gene circuits that allow the cells to respond to their environments.

Stay in the loop with our technology! From MMPower to MMportal you can ensure your patients get the best Clinical Intell...
04/18/2025

Stay in the loop with our technology! From MMPower to MMportal you can ensure your patients get the best Clinical Intelligence On-Demand. 💻 🧬

Learn more about how we can help you at www.molecularmatch.com

Advanced clinical informatics knowledge base MMPower, a dynamic molecular search engine.

Address

2450 Holcombe Boulevard
Houston, TX
77021

Telephone

+17135896499

Website

Alerts

Be the first to know and let us send you an email when MolecularMatch posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category